The role of neuropeptides in suicidal behavior: A systematic review

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Serafini, Gianluca ^a   Pompili, Maurizio ^a   Lindqvist, Daniel ^b   Dwivedi, Yogesh ^c   Girardi, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; CHOLECYSTOKININ; CORTICOTROPIN RELEASING FACTOR; DYNORPHIN; GALANIN; NERVE GROWTH FACTOR; NEUROPEPTIDE; NEUROPEPTIDE Y; OREXIN; OXYTOCIN; SUBSTANCE P; SIGNAL PEPTIDE; OREXINS;

HUMAN; INFORMATION RETRIEVAL; NEUROMODULATION; PATHOPHYSIOLOGY; PEER REVIEW; REVIEW; RISK ASSESSMENT; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW; META ANALYSIS; METABOLISM; SUICIDE;

ARGININE VASOPRESSIN; CORTICOTROPIN-RELEASING HORMONE; DYNORPHINS; GALANIN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEUROPEPTIDES; OREXINS; OXYTOCIN; SUBSTANCE P; SUICIDE;

EID: 84883169146     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/687575     Document Type: Review

References (146)

1. Goldsmith S. K., Pellmar T. C., Kleinman A. M., Bunney W. E., Reducing Suicide 2002 Washington, DC, USA Institute of Medicine of the US National Academies of Science
2. Simon R. I., Hales R. E., Textbook of Suicide Assessment and Management 2006 Washington, DC, USA American Psychiatric Press
3. World Health Organization (WHO), International suicide rates. http://www.who.int/mental-health/prevention/suicide/country-reports/en/index. html
4. Tondo L., Isacsson G., Baldessarini R. J., Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs 2003 17 7 491 511 2-s2.0-0038281515 10.2165/00023210-200317070-00003
5. Kessler R. C., Berglund P., Borges G., Nock M., Wang P. S., Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990-1992 to 2001-2003. Journal of the American Medical Association 2005 293 20 2487 2495 2-s2.0-18944368636 10.1001/jama.293.20.2487
6. Roy A., Sadock B. J., Sadock V. A., Suicide. Kaplan and Sadock's Comprehensive Textbook of Psychaitry 2000 2 7th Philadelphia, Pa, USA Lippincott Willians and Wilkins 2031 2040
7. Pompili M., Innamorati M., Rihmer Z., Gonda X., Serafini G., Akiskal H., Amore M., Niolu C., Sher L., Tatarelli R., Perugi G., Girardi P., Cyclothymic-depressive-anxious temperament pattern is related to suicide risk in 346 patients with major mood disorders. Journal of Affective Disorders 2012 136 3 405 411 2-s2.0-84857367375 10.1016/j.jad.2011.11.011
8. Pompili M., Rihmer Z., Akiskal H., Amore M., Gonda X., Innamorati M., Lester D., Perugi G., Serafini G., Telesforo L., Tatarelli R., Girardi P., Temperaments mediate suicide risk and psychopathology among patients with bipolar disorders. Comprehensive Psychiatry 2012 53 3 280 285 2-s2.0-84858796931 10.1016/j.comppsych.2011.04.004
9. Pompili M., Serafini G., Innamorati M., Lester D., Shrivastava A., Girardi P., Nordentoft M., Suicide risk in first episode psychosis: a selective review of the current literature. Schizophrenia Research 2011 129 1 1 11 2-s2.0-79956134444 10.1016/j.schres.2011.03.008
10. Serafini G., Pompili M., Innamorati M., Fusar-Poli P., Akiskal H. S., Rihmer Z., Lester D., Romano A., De Oliveira I. R., Strusi L., Ferracuti S., Girardi P., Tatarelli R., Affective temperamental profiles are associated with white matter hyperintensity and suicidal risk in patients with mood disorders. Journal of Affective Disorders 2011 129 1-3 47 55 2-s2.0-79851514794 10.1016/j.jad.2010.07.020
11. Serafini G., Pompili M., Innamorati M., Giordano G., Montebovi F., Sher L., Dwivedi Y., Girardi P., The role of microRNAs in synaptic plasticity, major affective disorders and suicidal behavior. Neuroscience Research 2012 73 179 190 2-s2.0-84860561647 10.1016/j.neures.2012.04.001
12. Innamorati M., Pompili M., Gonda X., Amore M., Serafini G., Niolu C., Lester D., Rutz W., Rihmer Z., Girardi P., Psychometric properties of the Gotland Scale for Depression in Italian psychiatric inpatients and its utility in the prediction of suicide risk. Journal of Affective Disorders 2011 132 1-2 99 103 2-s2.0-79958129591 10.1016/j.jad.2011.02.003
13. Maris R. W., Suicide. The Lancet 2002 360 9329 319 326 2-s2.0-0037183246 10.1016/S0140-6736(02)09556-9
14. Hawton K., van Heeringen K., Suicide. The Lancet 2009 373 9672 1372 1381 2-s2.0-64349104074 10.1016/S0140-6736(09)60372-X
15. Baca-Garcia E., Diaz-Sastre C., García Resa E., Blasco H., Braquehais Conesa D., Oquendo M. A., Saiz-Ruiz J., De Leon J., Suicide attempts and impulsivity. European Archives of Psychiatry & Clinical Neuroscience 2005 255 2 152 156 2-s2.0-17644382256 10.1007/s00406-004-0549-3
16. Gvion Y., Apte A., Aggression, impulsivity, and suicide behavior: a review of the literature. Archives of Suicide Research 2011 15 2 93 112 2-s2.0-79956082309 10.1080/13811118.2011.565265
17. Corruble E., Benyamina A., Bayle F., Falissard B., Hardy P., Understanding impulsivity in severe depression? A psychometrical contribution. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2003 27 5 829 833 2-s2.0-0043133766 10.1016/S0278-5846(03)00115-5
18. Plutchik R., Van Praag H. M., The measurement of suicidality, aggressivity and impulsivity. Clinical Neuropharmacology 1986 9 supplement 4 S380 S382
19. Beck A. T., Herman I., Schuyler D., Beck A. T., Resnick H. L. P., Lettieri D., Development of suicidal intent scales. The Prediction of Suicide 1974 Charles Press 45 46
20. McGonigle P., Peptide therapeutics for CNS indications. Biochemical Pharmacology 2012 83 5 559 566 2-s2.0-84856103580 10.1016/j.bcp.2011.10.014
21. Keck M. E., Ohl F., Holsboer F., Müller M. B., Listening to mutant mice: a spotlight on the role of CRF/CRF receptor systems in affective disorders. Neuroscience & Biobehavioral Reviews 2005 29 4-5 867 889 2-s2.0-19944414033 10.1016/j.neubiorev.2005.03.003
22. Panksepp J., The neurochemistry of behavior. Annual Review of Psychology 1986 37 77 107 2-s2.0-0022583868
23. Alldredge B., Pathogenic involvement of neuropeptides in anxiety and depression. Neuropeptides 2010 44 3 215 224 2-s2.0-77951204769 10.1016/j.npep.2009.12.014
24. Ludwig M., Are neuropeptides brain hormones? Journal of Neuroendocrinology 2011 23 4 381 382 2-s2.0-79952642768 10.1111/j.1365-2826. 2011.02115.x
25. Hökfelt T., Broberger C., Xu Z.-Q. D., Sergeyev V., Ubink R., Diez M., Neuropeptides-an overview. Neuropharmacology 2000 39 8 1337 1356 2-s2.0-0043131153 10.1016/S0028-3908(00)00010-1
26. Harro J., CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies. Amino Acids 2006 31 3 215 230 2-s2.0-33749555851 10.1007/s00726-006-0334-x
27. Valentino R. J., Commons K. G., Peptides that fine-tune the serotonin system. Neuropeptides 2005 39 1 1 8 2-s2.0-14644442955 10.1016/j.npep.2004.09. 005
28. Gold P. W., Chrousos G., Kellner C., Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. American Journal of Psychiatry 1984 141 5 619 627 2-s2.0-0021282106
29. Holsboer F., The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000 23 5 477 501 2-s2.0-0033797445 10.1016/S0893- 133X(00)00159-7
30. Keck M. E., Welt T., Müller M. B., Uhr M., Ohl F., Wigger A., Toschi N., Holsboer F., Landgraf R., Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology 2003 28 2 235 243 2-s2.0-0037311629
31. Sherrin T., Heng K. Y. C., Zhu Y. Z., Tang Y. M., Lau G., Tan C. H., Cholecystokinin-B receptor gene expression in cerebellum, pre-frontal cortex and cingulate gyrus and its association with suicide. Neuroscience Letters 2004 357 2 107 110 2-s2.0-1242269806 10.1016/j.neulet.2003.11.072
32. Harro J., Marcusson J., Oreland L., Alterations in brain cholecystokinin receptors in suicide victims. European Neuropsychopharmacology 1992 2 1 57 63 2-s2.0-0026830365
33. Westrin Å., Ekman R., Träskman-Bendz L., Alterations of corticotropin releasing hormone (CRH) and neuropeptide Y (NPY) plasma levels in mood disorder patients with a recent suicide attempt. European Neuropsychopharmacology 1999 9 3 205 211 2-s2.0-0033044550 10.1016/S0924- 977X(98)00026-1
34. Widdowson P. S., Ordway G. A., Halaris A. E., Reduced neuropeptide Y concentrations in suicide brain. Journal of Neurochemistry 1992 59 1 73 80 2-s2.0-0026689953 10.1111/j.1471-4159.1992.tb08877.x
35. Heilig M., Colmers W. F., Wahlestedt C., Neuropeptide Y in relation to behaviour and psychiatric disorders. Biology of Neuropeptide Y and Related Peptides 1993 Totowa, NJ, USA Humana Press 511 554
36. Moher D., Cook D. J., Eastwood S., Olkin I., Rennie D., Stroup D. F., Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. QUOROM Group. The British Journal of Surgery 2000 87 11 1448 1454 2-s2.0-0034320074
37. Heinrichs S. C., Koob G. F., Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation. Journal of Pharmacology and Experimental Therapeutics 2004 311 2 427 440 2-s2.0-4644285709 10.1124/jpet.103.052092
38. Nemeroff C. B., Vale W. W., The neurobiology of depression: inroads to treatment and new drug discovery. Journal of Clinical Psychiatry 2005 66 supplement 7 5 13 2-s2.0-25144441630
39. Kehne J. H., The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. CNS & Neurological Disorders-Drug Targets 2007 6 3 163 182 2-s2.0-34250316984 10.2174/ 187152707780619344
40. Pompili M., Serafini G., Innamorati M., Möller-Leimkühler A. M., Giupponi G., Girardi P., Tatarelli R., Lester D., The hypothalamic- pituitary-adrenal axis and serotonin abnormalities: a selective overview for the implications of suicide prevention. European Archives of Psychiatry & Clinical Neuroscience 2010 260 8 583 600 2-s2.0-78751576032 10.1007/s00406-010- 0108-z
41. Nemeroff C. B., Bissette G., Akil H., Fink M., Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, β -endorphin and somatostatin. British Journal of Psychiatry 1991 158 59 63 2-s2.0-0026027462
42. Stout S. C., Owens M. J., Nemeroff C. B., Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary- adrenal axis activity by stress and chronic antidepressant treatment. Journal of Pharmacology and Experimental Therapeutics 2002 300 3 1085 1092 2-s2.0-0036175309 10.1124/jpet.300.3.1085
43. Holsboer F., The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000 23 5 477 501 2-s2.0-0033797445 10.1016/S0893- 133X(00)00159-7
44. Nemeroff C. B., Widerlov E., Bissette G., Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984 226 4680 1342 1344 2-s2.0-0021714606
45. Bissette G., Klimek V., Pan J., Stockmeier C., Ordway G., Elevated concentrations of CRF in the locus coeruleus of depressed subjects. Neuropsychopharmacology 2003 28 7 1328 1335 2-s2.0-0042423405 10.1038/sj.npp.1300191
46. Merali Z., Du L., Hrdina P., Palkovits M., Faludi G., Poulter M. O., Anisman H., Dysregulation in the suicide brain: mRNA expression of corticotropinreleasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. Journal of Neuroscience 2004 24 6 1478 1485 2-s2.0-1242314197 10.1523/JNEUROSCI.4734-03.2004
47. Nemeroff C. B., Owens M. J., Bissette G., Andorn A. C., Stanley M., Reduced corticotropin releasing factor binding sites in the frontral cortex of suicide victims. Archives of General Psychiatry 1988 45 6 577 579 2-s2.0-0023927320
48. Makino S., Smith M. A., Gold P. W., Increased expression of corticotropin-releasing hormone and vasopressin messenger ribonucleic acid (mRNA) in the hypothalamic paraventricular nucleus during repeated stress: association with reduction in glucocorticoid receptor mRNA levels. Endocrinology 1995 136 8 3299 3309 2-s2.0-0029126692 10.1210/en.136.8.3299
49. Forster G. L., Pringle R. B., Mouw N. J., Vuong S. M., Watt M. J., Burke A. R., Lowry C. A., Summers C. H., Renner K. J., Corticotropin-releasing factor in the dorsal raphe nucleus increases medial prefrontal cortical serotonin via type 2 receptors and median raphe nucleus activity. European Journal of Neuroscience 2008 28 2 299 310 2-s2.0-48249090408 10.1111/j.1460-9568.2008. 06333.x
50. Liu Z., Zhu F., Wang G., Xiao Z., Wang H., Tang J., Wang X., Qiu D., Liu W., Cao Z., Li W., Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depression. Neuroscience Letters 2006 404 3 358 362 2-s2.0-33746317031 10.1016/j.neulet.2006.06.016
51. Liu Z., Zhu F., Wang G., Xiao Z., Tang J., Liu W., Wang H., Liu H., Wang X., Wu Y., Cao Z., Li W., Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neuroscience Letters 2007 414 2 155 158 2-s2.0-33847015598 10.1016/j.neulet.2006.12.013
52. Keck M. E., Kern N., Erhardt A., Unschuld P. G., Ising M., Salyakina D., Müller M. B., Knorr C. C., Lieb R., Hohoff C., Krakowitzky P., Maier W., Bandelow B., Fritze J., Deckert J., Holsboer F., Müller-Myhsok B., Binder E. B., Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. American Journal of Medical Genetics B 2008 147 7 1196 1204 2-s2.0-55349106933 10.1002/ajmg.b.30750
53. Bradley R. G., Binder E. B., Epstein M. P., Tang Y., Nair H. P., Liu W., Gillespie C. F., Berg T., Evces M., Newport D. J., Stowe Z. N., Heim C. M., Nemeroff C. B., Schwartz A., Cubells J. F., Ressler K. J., Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Archives of General Psychiatry 2008 65 2 190 200 2-s2.0-38949159163 10.1001/archgenpsychiatry.2007.26
54. Binneman B., Feltner D., Kolluri S., Shi Y., Qiu R., Stiger T., A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. American Journal of Psychiatry 2008 165 5 617 620 2-s2.0-43949134527 10.1176/appi.ajp.2008.07071199
55. Caldwell H. K., Lee H.-J., Macbeth A. H., Young W. S. III, Vasopressin: behavioral roles of an "original" neuropeptide. Progress in Neurobiology 2008 84 1 1 24 2-s2.0-37149016771 10.1016/j.pneurobio.2007.10.007
56. van Londen L., Goekoop J. G., van Kempen G. M. J., Frankhuijzen- Sierevogel A. C., Wiegant V. M., Van Der Velde E. A., De Wied D., Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 1997 17 4 284 292 2-s2.0-0030869685 10.1016/S0893- 133X(97)00054-7
57. Purba J. S., Hoogendijk W. J. G., Hofman M. A., Swaab D. F., Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Archives of General Psychiatry 1996 53 2 137 143 2-s2.0-0030032350
58. Schmidt E. D., Binnekade R., Janszen A. W. J. W., Tilders F. J. H., Short stressor induced long-lasting increases in vasopressin stores in hypothalamic corticotropin-releasing hormone (CRH) neurons in adult rats. Journal of Neuroendocrinology 1996 8 9 703 712 2-s2.0-0029812377
59. Volpi S., Rabadan-Diehl C., Aguilera G., Vasopressinergic regulation of the hypothalamic pituitary adrenal axis and stress adaptation. Stress 2004 7 2 75 83 2-s2.0-3543005971 10.1080/10253890410001733535
60. Dinan T. G., Scott L. V., Anatomy of melancholia: focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressin. Journal of Anatomy 2005 207 3 259 264 2-s2.0-24944571838 10.1111/j.1469-7580. 2005.00443.x
61. Dempster E. L., Burcescu I., Wigg K., Kiss E., Baji I., Gadoros J., Tamás Z., Kennedy J. L., Vetró Á., Kovacs M., Barr C. L., Evidence of an association between the vasopressin V1b receptor gene (AVPR1B) and childhood-onset mood disorders. Archives of General Psychiatry 2007 64 10 1189 1195 2-s2.0-34948879533 10.1001/archpsyc.64.10.1189
62. Egashira N., Tanoue A., Matsuda T., Koushi E., Harada S., Takano Y., Tsujimoto G., Mishima K., Iwasaki K., Fujiwara M., Impaired social interaction and reduced anxiety-related behavior in vasopressin V1a receptor knockout mice. Behavioural Brain Research 2007 178 1 123 127 2-s2.0-33846951809 10.1016/j.bbr.2006.12.009
63. Bleickardt C. J., Mullins D. E., MacSweeney C. P., Werner B. J., Pond A. J., Guzzi M. F., Martin F. D. C., Varty G. B., Hodgson R. A., Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior. Psychopharmacology 2009 202 4 711 718 2-s2.0-59849111655 10.1007/s00213-008- 1354-x
64. Aguilera G., Subburaju S., Young S., Chen J., The parvocellular vasopressinergic system and responsiveness of the hypothalamic pituitary adrenal axis during chronic stress. Progress in Brain Research 2008 170 29 39 2-s2.0-47549085728 10.1016/S0079-6123(08)00403-2
65. Simon N. G., Guillon C., Fabio K., Heindel N. D., Lu S.-F., Miller M., Ferris C. F., Brownstein M. J., Garripa C., Koppel G. A., Vasopressin antagonists as anxiolytics and antidepressants: recent developments. Recent Patents on CNS Drug Discovery 2008 3 2 77 93 2-s2.0-49149103265 10.2174/157488908784534586
66. Pedersen C. A., Boccia M. L., Oxytocin antagonism alters rat dams' oral grooming and upright posturing over pups. Physiology & Behavior 2003 80 2-3 233 241 2-s2.0-0344153935 10.1016/j.physbeh.2003.07.011
67. Benelli A., Bertolini A., Poggioli R., Menozzi B., Basaglia R., Arletti R., Polymodal dose-response curve for oxytocin in the social recognition test. Neuropeptides 1995 28 4 251 255 2-s2.0-0028958482 10.1016/0143-4179(95)90029-2
68. Rimmele U., Hediger K., Heinrichs M., Klaver P., Oxytocin makes a face in memory familiar. Journal of Neuroscience 2009 29 1 38 42 2-s2.0-58149383383 10.1523/JNEUROSCI.4260-08.2009
69. Stachowiak A., Macchi C., Nussdorfer G. G., Malendowicz L. K., Effects of oxytocin on the function and morphology of the rat adrenal cortex: in vitro and in vivo investigations. Research in Experimental Medicine 1995 195 5 265 274 2-s2.0-0028885960
70. Legros J.-J., Inhibitory effect of oxytocin on corticotrope function in humans: are vasopressin and oxytocin ying-yang neurohormones? Psychoneuroendocrinology 2001 26 7 649 655 2-s2.0-0034907188 10.1016/S0306-4530(01)00018-X
71. Ring R. H., Malberg J. E., Potestio L., Ping J., Boikess S., Luo B., Schechter L. E., Rizzo S., Rahman Z., Rosenzweig-Lipson S., Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology 2006 185 2 218 225 2-s2.0-33644848493 10.1007/s00213-005-0293-z
72. Ring R. H., Schechter L. E., Leonard S. K., Dwyer J. M., Platt B. J., Graf R., Grauer S., Pulicicchio C., Resnick L., Rahman Z., Sukoff Rizzo S. J., Luo B., Beyer C. E., Logue S. F., Marquis K. L., Hughes Z. A., Rosenzweig-Lipson S., Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology 2010 58 1 69 77 2-s2.0-71549136792 10.1016/j.neuropharm.2009.07.016
73. Kirsch P., Esslinger C., Chen Q., Mier D., Lis S., Siddhanti S., Gruppe H., Mattay V. S., Gallhofer B., Meyer-Lindenberg A., Oxytocin modulates neural circuitry for social cognition and fear in humans. Journal of Neuroscience 2005 25 49 11489 11493 2-s2.0-30544438866 10.1523/JNEUROSCI.3984-05.2005
74. Scantamburlo G., Hansenne M., Fuchs S., Pitchot W., Maréchal P., Pequeux C., Ansseau M., Legros J. J., Plasma oxytocin levels and anxiety in patients with major depression. Psychoneuroendocrinology 2007 32 4 407 410 2-s2.0-34247257273 10.1016/j.psyneuen.2007.01.009
75. Uvnas-Moberg K., Alster P., Svensson T. H., Amperozide and clozapine but not haloperidol or raclopride increase the secretion of oxytocin in rats. Psychopharmacology 1992 109 4 473 476 2-s2.0-0026460319 10.1007/BF02247726
76. Jokinen J., Chatzittofis A., Hellström C., Nordström P., Uvnäs-Moberg K., Åsberg M., Low CSF oxytocin reflects high intent in suicide attempters. Psychoneuroendocrinology 2012 37 4 482 490 2-s2.0-84857192685 10.1016/j.psyneuen.2011.07.016
77. Feifel D., Reza T., Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology 1999 141 1 93 98 2-s2.0-0032964581 10.1007/s002130050811
78. Feifel D., MacDonald K., Nguyen A., Cobb P., Warlan H., Galangue B., Minassian A., Becker O., Cooper J., Perry W., Lefebvre M., Gonzales J., Hadley A., Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biological Psychiatry 2010 68 7 678 680 2-s2.0-77956932186 10.1016/j.biopsych. 2010.04.039
79. Modahl C., Green L., Fein D., Morris M., Waterhouse L., Feinstein C., Levin H., Plasma oxytocin levels in autistic children. Biological Psychiatry 1998 43 4 270 277 2-s2.0-0032519523 10.1016/S0006-3223(97)00439-3
80. Yrigollen C. M., Han S. S., Kochetkova A., Babitz T., Chang J. T., Volkmar F. R., Leckman J. F., Grigorenko E. L., Genes controlling affiliative behavior as candidate genes for autism. Biological Psychiatry 2008 63 10 911 916 2-s2.0-42649094425 10.1016/j.biopsych.2007.11.015
81. Hollander E., Bartz J., Chaplin W., Phillips A., Sumner J., Soorya L., Anagnostou E., Wasserman S., Oxytocin increases retention of social cognition in autism. Biological Psychiatry 2007 61 4 498 503 2-s2.0-33846624633 10.1016/j.biopsych.2006.05.030
82. Hollander E., Novotny S., Hanratty M., Yaffe R., DeCaria C. M., Aronowitz B. R., Mosovich S., Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology 2003 28 1 193 198 2-s2.0-0037209159
83. Lindqvist D., Janelidze S., Erhardt S., Träskman-Bendz L., Engström G., Brundin L., CSF biomarkers in suicide attempters-a principal component analysis. Acta Psychiatrica Scandinavica 2011 124 1 52 61 2-s2.0-79958743342 10.1111/j.1600-0447.2010.01655.x
84. Stanley B., Sher L., Wilson S., Ekman R., Huang Y.-Y., Mann J. J., Non-suicidal self-injurious behavior, endogenous opioids and monoamine neurotransmitters. Journal of Affective Disorders 2010 124 1-2 134 140 2-s2.0-77952289482 10.1016/j.jad.2009.10.028
85. Brundin L., Björkqvist M., Träskman-Bendz L., Petersén A., Increased orexin levels in the cerebrospinal fluid the first year after a suicide attempt. Journal of Affective Disorders 2009 113 179 182
86. Pitchot W., Scantamburlo G., Pinto E., Hansenne M., Reggers J., Ansseau M., Legros J.-J., Vasopressin-neurophysin and DST in major depression: relationship with suicidal behavior. Journal of Psychiatric Research 2008 42 8 684 688 2-s2.0-43049143091 10.1016/j.jpsychires.2007.07.007
87. Brundin L., Björkqvist M., Petersén Å., Träskman-Bendz L., Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. European Neuropsychopharmacology 2007 17 9 573 579 2-s2.0-34447531745 10.1016/j.euroneuro.2007.01.005
88. Brundin L., Petersén A., Bjrkqvist M., Träskman-Bendz L., Orexin and psychiatric symptoms in suicide attempters. Journal of Affective Disorders 2007 100 1-3 259 263
89. Austin M. C., Janosky J. E., Murphy H. A., Increased corticotropin- releasing hormone immunoreactivity in monoamine-containing pontine nuclei of depressed suicide men. Molecular Psychiatry 2003 8 3 324 332 2-s2.0-0037499680 10.1038/sj.mp.4001250
90. Merali Z., Kent P., Du L., Hrdina P., Palkovits M., Faludi G., Poulter M. O., Bédard T., Anisman H., Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjects. Biological Psychiatry 2006 59 7 594 602 2-s2.0-33644822488 10.1016/j.biopsych.2005.08.008
91. Brunner J., Keck M. E., Landgraf R., Uhr M., Namendorf C., Bronisch T., Vasopressin in CSF and plasma in depressed suicide attempters: preliminary results. European Neuropsychopharmacology 2002 12 5 489 494 2-s2.0-0036788870 10.1016/S0924-977X(02)00071-8
92. Caberlotto L., Hurd Y. L., Neuropeptide Y Y1 and Y2 receptor mRNA expression in the prefrontal cortex of psychiatric subjects: relationship of Y2 subtype to suicidal behavior. Neuropsychopharmacology 2001 25 1 91 97 2-s2.0-0035002349 10.1016/S0893-133X(00)00231-1
93. Inder W. J., Donald R. A., Prickett T. C. R., Frampton C. M., Sullivan P. F., Mulder R. T., Joyce P. R., Arginine vasopressin is associated with hypercortisolemia and suicide attempts in depression. Biological Psychiatry 1997 42 8 744 747 2-s2.0-0030861824 10.1016/S0006-3223(97)00301-6
94. Olsson A., Regnéll G., Träskman-Bendz L., Ekman R., Westrin Å., Cerebrospinal neuropeptide Y and substance P in suicide attempters during long-term antidepressant treatment. European Neuropsychopharmacology 2004 14 6 479 485 2-s2.0-10344222621 10.1016/j.euroneuro.2004.01.005
95. Westrin A., Ekman R., Regnéll G., Träskman-Bendz L., A follow up study of suicide attempters: increase of CSF-somatostatin but no change in CSF-CRH. European Neuropsychopharmacology 2001 11 2 135 143 2-s2.0-0035058711 10.1016/S0924-977X(01)00073-6
96. Westrin Å., Ekman R., Träskman-Bendz L., High delta sleep-inducing peptide-like immunoreactivity in plasma in suicidal patients with major depressive disorder. Biological Psychiatry 1998 43 10 734 739 2-s2.0-0032523827 10.1016/S0006-3223(97)00254-0
97. Westrin Å., Engstöm G., Ekman R., Träskman-Bendz L., Correlations between plasma-neuropeptides and temperament dimensions differ between suicidal patients and healthy controls. Journal of Affective Disorders 1998 49 1 45 54 2-s2.0-0032054448 10.1016/S0165-0327(97)00197-3
98. Roy A., Neuropeptides in relation to suicidal behavior in depression. Neuropsychobiology 1993 28 4 184 186 2-s2.0-0027376822
99. Ordway G. A., Stockmeier C. A., Meltzer H. Y., Overholser J. C., Jaconetta S., Widdowson P. S., Neuropeptide Y in frontal cortex is not altered in major depression. Journal of Neurochemistry 1995 65 4 1646 1650 2-s2.0-0029103163
100. Träskman-Bendz L., Ekman R., Regnéll G., Öhman R., HPA-related CSF neuropeptides in suicide attempters. European Neuropsychopharmacology 1992 2 2 99 106 2-s2.0-0026870766
101. Scarone S., Gambini O., Calabrese G., Sacerdote P., Bruni M., Carucci M., Panerai A. E., Asymmetrical distribution of beta-endorphin in cerebral hemispheres of suicides: preliminary data. Psychiatry Research 1990 32 2 159 166 2-s2.0-0025332919 10.1016/0165-1781(90)90082-G
102. Maes M., Vandewoude M., Schotte C., Martin M., Blockx P., Scharpe S., Cosyns P., Hypothalamic-pituitary-adrenal and -thyroid axis dysfunctions and decrements in the availability of L-tryptophan as biological markers of suicidal ideation in major depressed females. Acta Psychiatrica Scandinavica 1989 80 1 13 17 2-s2.0-0024370134
103. Kuteeva E., Hökfelt T., Wardi T., Ogren S. O., Galanin, galanin receptor subtypes and depression-like behaviour. Cellular and Molecular Life Sciences 2008 65 12 1854 1863 2-s2.0-45849132020 10.1007/s00018-008-8160-9
104. Karlsson R.-M., Holmes A., Galanin as a modulator of anxiety and depression and a therapeutic target for affective disease. Amino Acids 2006 31 3 231 239 2-s2.0-33749574737 10.1007/s00726-006-0336-8
105. Tortorella C., Neri G., Nussdorfer G. G., Galanin in the regulation of the hypothalamic-pituitary-adrenal axis (review). International Journal of Molecular Medicine 2007 19 4 639 647 2-s2.0-34247895507
106. Ogren S. O., Kuteeva E., Hökfelt T., Kehr J., Galanin receptor antagonists: a potential novel pharmacological treatment for mood disorders. CNS Drugs 2006 20 8 633 654 2-s2.0-33746564580 10.2165/00023210-200620080-00003
107. Weiss J. M., Boss-Williams K. A., Moore J. P., Demetrikopoulos M. K., Ritchie J. C., West C. H. K., Testing the hypothesis that locus coeruleus hyperactivity produces depression-related changes via galanin. Neuropeptides 2005 39 3 281 287 2-s2.0-20444402284 10.1016/j.npep.2004.12.028
108. Ogren S. O., Razani H., Elvander-Tottie E., Kehr J., The neuropeptide galanin as an in vivo modulator of brain 5-HT1A receptors: possible relevance for affective disorders. Physiology & Behavior 2007 92 1-2 172 179 2-s2.0-34548484158 10.1016/j.physbeh.2007.05.022
109. Swanson C. J., Blackburn T. P., Zhang X., Zheng K., Xu Z.-Q. D., Hökfelt T., Wolinsky T. D., Konkel M. J., Chen H., Zhong H., Walker M. W., Craig D. A., Gerald C. P. G., Branchek T. A., Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proceedings of the National Academy of Sciences of the United States of America 2005 102 48 17489 17494 2-s2.0-28444496672 10.1073/pnas.0508970102
110. Elliott-Hunt C. R., Pope R. J. P., Vanderplank P., Wynick D., Activation of the galanin receptor 2 (GalR2) protects the hippocampus from neuronal damage. Journal of Neurochemistry 2007 100 3 780 789 2-s2.0-33846226396 10.1111/j.1471-4159.2006.04239.x
111. Ebner K., Muigg P., Singewald G., Singewald N., Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Annals of the New York Academy of Sciences 2008 1144 61 73 2-s2.0-56649105314 10.1196/annals.1418.018
112. Blier P., Gobbi G., Haddjeri N., Santarelli L., Mathew G., Hen R., Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. Journal of Psychiatry and Neuroscience 2004 29 3 208 218 2-s2.0-3042611638
113. Ma Q.-P., Bleasdale C., Modulation of brain stem monoamines and γ -aminobutyric acid by NKI receptors in rats. NeuroReport 2002 13 14 1809 1812 2-s2.0-0037038117
114. Ebner K., Singewald N., Stress-induced release of substance P in the locus coeruleus modulates cortical noradrenaline release. Naunyn-Schmiedeberg's Archives of Pharmacology 2007 376 1-2 73 82 2-s2.0-38449098153
115. Ebner K., Rupniak N. M., Saria A., Singewald N., Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proceedings of the National Academy of Sciences of the United States of America 2004 101 12 4280 4285 2-s2.0-1642488331 10.1073/pnas.0400794101
116. Ebner K., Sartori S. B., Singewald N., Tachykinin receptors as therapeutic targets in stress-related disorders. Current Pharmaceutical Design 2009 15 14 1647 1674 2-s2.0-67650569457 10.2174/138161209788168074
117. Furmark T., Appel L., Michelgård Å., Wahlstedt K., Åhs F., Zancan S., Jacobsson E., Flyckt K., Grohp M., Bergström M., Pich E. M., Nilsson L.-G., Bani M., Långström B., Fredrikson M., Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biological Psychiatry 2005 58 2 132 142 2-s2.0-22444442937 10.1016/j.biopsych.2005.03.029
118. Louis C., Stemmelin J., Boulay D., Bergis O., Cohen C., Griebel G., Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. Pharmacology Biochemistry and Behavior 2008 89 1 36 45 2-s2.0-38049103986 10.1016/j.pbb.2007.10.020
119. Smith P. W., Dawson L. A., Neurokinin 3 (NK3) receptor modulators for the treatment of psychiatric disorders. Recent Patents on CNS Drug Discovery 2008 3 1 1 15 2-s2.0-38949131438 10.2174/157488908783421447
120. Sawchenko P. E., Swanson L. W., Grzanna R., Colocalization of neuropeptide Y immunoreactivity in brainstem catecholaminergic neurons that project to the paraventricular nucleus of the hypothalamus. Journal of Comparative Neurology 1985 241 2 138 153 2-s2.0-0022409978
121. Redrobe J. P., Dumont Y., Fournier A., Baker G. B., Quirion R., Role of serotonin (5-HT) in the antidepressant-like properties of neuropeptide Y (NPY) in the mouse forced swim test. Peptides 2005 26 8 1394 1400 2-s2.0-22544481724 10.1016/j.peptides.2005.03.029
122. Heilig M., Soderpalm B., Engel J. A., Widerlov E., Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology 1989 98 4 524 529 2-s2.0-0024310089
123. Kask A., Harro J., von Hörsten S., Redrobe J. P., Dumont Y., Quirion R., The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neuroscience & Biobehavioral Reviews 2002 26 3 259 283 2-s2.0-0036111124 10.1016/S0149-7634(01)00066-5
124. Nakajima M., Inui A., Asakawa A., Momose K., Ueno N., Teranishi A., Baba S., Kasuga M., Neuropeptide Y produces anxiety via Y2-type receptors. Peptides 1998 19 2 359 363 2-s2.0-0032005127 10.1016/S0196-9781(97)00298-2
125. Sørensen G., Lindberg C., Wörtwein G., Bolwig T. G., Woldbye D. P. D., Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation. Journal of Neuroscience Research 2004 77 5 723 729 2-s2.0-4444346012 10.1002/jnr.20200
126. Heilig M., The NPY system in stress, anxiety and depression. Neuropeptides 2004 38 4 213 224 2-s2.0-4344622379 10.1016/j.npep.2004.05.002
127. Sajdyk T. J., Fitz S. D., Shekhar A., The role of neuropeptide Y in the amygdala on corticotropin-releasing factor receptor-mediated behavioral stress responses in the rat. Stress 2006 9 1 21 28 2-s2.0-33744999429 10.1080/10253890600557315
128. Eaton K., Sallee F. R., Sah R., Relevance of neuropeptide Y (NPY) in psychiatry. Current Topics in Medicinal Chemistry 2007 7 17 1645 1659 2-s2.0-36248946217 10.2174/156802607782341037
129. Lindefors N., Linden A., Brene S., Sedvall G., Persson H., CCK peptides and mRNA in the human brain. Progress in Neurobiology 1993 40 6 671 690 2-s2.0-0027476729 10.1016/0301-0082(93)90010-P
130. Vaccarino F. J., Rankin J., Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: evidence for rostral-caudal differences in accumbens CCK function. Behavioral Neuroscience 1989 103 4 831 836 2-s2.0-0024442198 10.1037/0735-7044.103.4.831
131. Crawley J. N., Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway. Journal of Neuroscience 1992 12 9 3380 3391 2-s2.0-0026783285
132. Goldstein A., Fischli W., Lowney L. I., Hunkapiller M., Hood L., Porcine pituitary dynorphin: complete amino acid sequence of the biologically active heptadecapeptide. Proceedings of the National Academy of Sciences of the United States of America 1981 78 11 7219 7223 2-s2.0-0019638380
133. Hegadoren K. M., O'Donnell T., Lanius R., Coupland N. J., Lacaze-Masmonteil N., The role of β -endorphin in the pathophysiology of major depression. Neuropeptides 2009 43 5 341 353 2-s2.0-70350104892 10.1016/j.npep.2009.06.004
134. De Lecea L., Kilduff T. S., Peyron C., Gao X.-B., Foye P. E., Danielson P. E., Fukuhara C., Battenberg E. L. F., Gautvik V. T., Bartlett F. S. II, Frankel W. N., Van Den Pol A. N., Bloom F. E., Gautvik K. M., Sutcliffe J. G., The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proceedings of the National Academy of Sciences of the United States of America 1998 95 1 322 327 2-s2.0-0008390266 10.1073/pnas.95.1.322
135. Date Y., Ueta Y., Yamashita H., Yamaguchi H., Matsukura S., Kangawa K., Sakurai T., Yanagisawa M., Nakazato M., Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proceedings of the National Academy of Sciences of the United States of America 1999 96 2 748 753 2-s2.0-0033582175 10.1073/pnas.96.2.748
136. Nambu T., Sakurai T., Mizukami K., Hosoya Y., Yanagisawa M., Goto K., Distribution of orexin neurons in the adult rat brain. Brain Research 1999 827 1-2 243 260 2-s2.0-0033535747 10.1016/S0006-8993(99)01336-0
137. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R. M., Tanaka H., Williams S. C., Richardson J. A., Kozlowski G. P., Wilson S., Arch J. R. S., Buckingham R. E., Haynes A. C., Carr S. A., Annan R. S., McNulty D. E., Liu W.-S., Terrett J. A., Elshourbagy N. A., Bergsma D. J., Yanagisawa M., Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998 92 4 573 585 2-s2.0-20244380014 10.1016/S0092-8674(00)80949-6
138. Stanley B., Traskman-Bendz L., Stanley M., The suicide assessment scale: a scale evaluating change in suicidal behavior. Psychopharmacology Bulletin 1986 22 1 200 205 2-s2.0-0022569997
139. Dumont Y., Morales-Medina J. C., Quirion R., Shioda S., Homma I., Kato N., Neuropeptide Y and its role in anxiety-related disorders. Transmitters and Modulators In Health and Disease 2009 Springer, Kato Bunmeisha 51 82
140. Thakker-Varia S., Alder J., Neuropeptides in depression: role of VGF. Behavioural Brain Research 2009 197 2 262 278 2-s2.0-58149512288 10.1016/j.bbr.2008.10.006
141. Kuteeva E., Wardi T., Lundström L., Sollenberg U., Langel Ü., Hökfelt T., Ogren S. O., Differential role of galanin receptors in the regulation of depression-like behavior and monoamine/stress-related genes at the cell body level. Neuropsychopharmacology 2008 33 11 2573 2585 2-s2.0-51749095053 10.1038/sj.npp.1301660
142. Biguet N. F., Buda M., Lamouroux A., Samolyk D., Mallet J., Time course of the changes of TH mRNA in rat brain and adrenal medulla after a single injection of reserpine. The EMBO Journal 1986 5 2 287 291 2-s2.0-0022665799
143. Berod A., Biguet N. F., Dumas S., Bloch B., Mallet J., Modulation of tyrosine hydroxylase gene expression in the central nervous system visualized by in situ hybridization. Proceedings of the National Academy of Sciences of the United States of America 1987 84 6 1699 1703 2-s2.0-0023194780
144. Holmes P. V., Caroline Blanchard D., Blanchard R. J., Brady L. S., Crawley J. N., Chronic social stress increases levels of preprogalanin mRNA in the rat locus coeruleus. Pharmacology Biochemistry and Behavior 1995 50 4 655 660 2-s2.0-0028953414 10.1016/0091-3057(94)00334-3
145. Morales-Medina J. C., Dumont Y., Quirion R., A possible role of neuropeptide Y in depression and stress. Brain Research 2010 1314 194 205 2-s2.0-75149114515 10.1016/j.brainres.2009.09.077
146. Griebel G., Holsboer F., Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nature Review Drug Discovery 2012 11 462 478